We have another important update to share.
Invivyd and the SPEAR (Spike Protein Elimination and Recovery) Study Group have announced plans to initiate their Phase 2 clinical trial of the monoclonal antibody VYD2311 for treatment — not just prevention — in people with Long COVID or COVID vaccine injury.
Key aspects of the planned Phase 2 trial:
• It will evaluate safety, translational biology, and exploratory clinical efficacy of VYD2311 in individuals with Long COVID or vaccine‑related injury.
• The design includes multiple high doses of the antibody and a double‑blind, placebo‑controlled structure.
• Participants will include people showing evidence of persistent infection or antigen presence, an important biological marker linked to Long COVID symptoms.
• The trial is expected to begin mid‑2026 — a significant milestone for research into Long COVID therapeutics.
Millions continue to suffer with persistent symptoms and disability — and until we test and develop effective treatments, there is no clear path to relief for many.
This planned Phase 2 trial is a major step toward understanding whether monoclonal antibodies like VYD2311 can actually help people living with Long COVID and chronic COVID‑related conditions. It complements prevention research already underway and underscores the importance of expanding clinical options beyond vaccines.
Read the full press release here:
⸻
We’ll continue advocating for equitable access, clinical trials, and science-backed policy in Canada.
Change is coming — let’s make sure it reaches those who need it most.
— Rowan